Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience

scientific article published on 13 March 2013

Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1009746529
P356DOI10.1186/1748-717X-8-58
P932PMC publication ID3610192
P698PubMed publication ID23497695

P2093author name stringSarah Laing
Anatoly Dritschilo
Sean P Collins
Kathryn L Taylor
Brian T Collins
John H Lynch
Joy S Kim
Keith Kowalczyk
Leonard N Chen
Simeng Suy
Siyuan Lei
Nancy A Dawson
Eric K Oermann
Viola Chen
Gerald P Batipps
Heather N Hanscom
Kevin G McGeagh
Pranay Krishnan
Gaurav Bandi
John Pahira
Sunghae Uhm
Andrew W Ju
P2860cites workA 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validityQ29547290
Stereotactic body radiotherapy for organ-confined prostate cancerQ33528163
The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological AssociationQ33846043
Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviationQ34193483
The International Index of Erectile Function (IIEF): a state-of-the-science reviewQ34769477
Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy.Q36127793
The radiobiology of prostate cancer including new aspects of fractionated radiotherapyQ36217139
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancerQ36604355
Hypofractionation for prostate cancer: a critical reviewQ37033108
Intrafractional motion of the prostate during hypofractionated radiotherapyQ37301004
Sexual function after stereotactic body radiotherapy for prostate cancer: results of a prospective clinical trialQ37688380
A survey of stereotactic body radiotherapy use in the United StatesQ39771088
Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomesQ41775778
Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapyQ42555504
Late gastrointestinal and urogenital side-effects after radiotherapy--incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancerQ44178299
Erectile aid use by men treated for localized prostate cancerQ44784365
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial resultsQ44927559
Predictors of response to sildenafil citrate following radiation therapy for prostate cancerQ46125033
Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-upQ46158698
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancerQ46224660
Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancerQ46343237
Comparison of validated instruments measuring sexual function in men.Q46377824
Posttreatment complications of early-stage prostate cancer patients: brachytherapy versus three-dimensional conformal radiation therapyQ46559971
Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes StudyQ46592554
Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifferenceQ48439178
Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancerQ48837209
Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancerQ49137789
Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study.Q52017308
Erectile function after prostate brachytherapy.Q53273439
Urinary symptom flare following I-125 prostate brachytherapy.Q53300115
Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.Q53505973
Temporal resolution of urinary morbidity following prostate brachytherapyQ73661199
An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinomaQ79452001
Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysisQ80195189
Quality of life and satisfaction with outcome among prostate-cancer survivorsQ80917895
PSA kinetics and PSA bounce following permanent seed prostate brachytherapyQ81298448
PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling timeQ81328456
Long-term urinary sequelae following 125iodine prostate brachytherapyQ81588069
Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trialQ82966826
Time of decline in sexual function after external beam radiotherapy for prostate cancerQ83733536
P921main subjectadaptive radiation therapyQ180507
prostate cancerQ181257
P304page(s)58
P577publication date2013-03-13
P1433published inRadiation OncologyQ2313370
P1476titleStereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience
P478volume8

Reverse relations

cites work (P2860)
Q42250155A Phase II Study of Stereotactic Body Radiation Therapy for Low-Intermediate-High-Risk Prostate Cancer Using Helical Tomotherapy: Dose-Volumetric Parameters Predicting Early Toxicity
Q38198096A clinical review on extreme hypofractionated stereotactic body radiation therapy for localized prostate cancer using nonrobotic linear accelerators
Q92531197A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma
Q41821780Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction
Q33659901Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer
Q38372450Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction
Q64988846Comparison of Late Urinary Symptoms Following SBRT and SBRT with IMRT Supplementation for Prostate Cancer.
Q48308100Comparison of multileaf collimator and conventional circular collimator systems in Cyberknife stereotactic radiotherapy
Q90646730Comparison of rectal dose reduction by a hydrogel spacer among 3D conformal radiotherapy, volumetric-modulated arc therapy, helical tomotherapy, CyberKnife and proton therapy
Q42638497Complementary and alternative medicine use and disclosure amongst Australian radiotherapy patients
Q48736026Conventionally Fractionationed Volumetric Arc Therapy versus Hypofractionated Stereotactic Body Radiotherapy: Quality of Life, Side Effects, and Prostate-Specific Antigen Kinetics in Localized Prostate Cancer
Q90429894Discovery of Metabolic Biomarkers Predicting Radiation Therapy Late Effects in Prostate Cancer Patients
Q55425041Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer.
Q46838608Dosimetric and radiobiological comparison of Cyberknife and Tomotherapy in stereotactic body radiotherapy for localized prostate cancer
Q37175207Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy
Q38550590Dysuria Following Stereotactic Body Radiation Therapy for Prostate Cancer
Q64228389Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer
Q38677828Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer
Q38276603Evolution of hypofractionated accelerated radiotherapy for prostate cancer - the sunnybrook experience
Q41633448First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
Q35174871Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
Q57280845Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline
Q38746814Hypofractionated helical tomotherapy (75 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term analysis of gastrointestinal and genitourinary toxicity
Q39456165Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study
Q26823218Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations
Q37547386Hypofractionated radiotherapy for localized prostate cancer
Q38863898Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?
Q38283897Hypofractionated radiotherapy for prostate cancer.
Q38780363Hypofractionated stereotactic body radiotherapy for localized prostate cancer - first Nordic clinical experience
Q37551757Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
Q40959958Image-guided hypofractionated proton beam therapy for low-risk prostate cancer: Analysis of quality of life and toxicity, PCG GU 002.
Q42953465Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer
Q48937281Initial experience with stereotactic body radiation therapy for localized prostate cancer using helical tomotherapy.
Q37627132Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity
Q42364887Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer
Q92839938Isolation and identification of cancer stem cells from PC3 human prostate carcinoma cell line
Q39007067Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer
Q92323677Linac-based stereotactic body radiation therapy vs moderate hypofractionated radiotherapy in prostate cancer: propensity-score based comparison of outcome and toxicity
Q41816565Long-term intra-fractional motion of the prostate using hydrogel spacer during Cyberknife® treatment for prostate cancer--a case report
Q59335949Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01)
Q91436232Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer
Q48238146Moderate hypofractionation for prostate cancer: A user's guide.
Q33985573Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer
Q37671472Optimal planning strategy among various arc arrangements for prostate stereotactic body radiotherapy with volumetric modulated arc therapy technique
Q41985869Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
Q41953259Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer
Q33851417Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer
Q38158080Potency preservation following stereotactic body radiation therapy for prostate cancer
Q39078034Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
Q34748877Proctitis following stereotactic body radiation therapy for prostate cancer
Q65001493Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review.
Q37522643Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer
Q35827490Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer
Q36387814Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer
Q51614445Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
Q34413524Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study
Q38172209Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer
Q37116581Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer
Q41276603Reducing rectal injury in men receiving prostate cancer radiation therapy: current perspectives
Q41836348Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap
Q97540700Risk of erectile dysfunction after modern radiotherapy for intact prostate cancer
Q38677018SBRT and extreme hypofractionation: A new era in prostate cancer treatments?
Q34487782SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines
Q36009944Sexual, irritative, and voiding outcomes, following stereotactic body radiation therapy for prostate cancer
Q88640217Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218
Q38982350Simple diagrammatic method to delineate male urethra in prostate cancer radiotherapy: an MRI based approach
Q34575533Stereotactic Body Radiation Therapy for Prostate Cancer: Review of Experience of a Multicenter Phase I/II Dose-Escalation Study
Q35233601Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
Q36426682Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry
Q44514013Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis
Q38268325Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Q90041948Stereotactic body radiation therapy in primary hepatocellular carcinoma: current status and future directions
Q37702326Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity
Q38243077Stereotactic body radiotherapy for primary prostate cancer: a systematic review
Q92374044Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes
Q42702939Stereotactic radiotherapy for prostate cancer: A review and future directions
Q37159100The Impact of Obesity on Patient Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer
Q30443893The RSSearch™ Registry: patterns of care and outcomes research on patients treated with stereotactic radiosurgery and stereotactic body radiotherapy
Q39200876The Role of Hypofractionated Radiotherapy in Prostate Cancer
Q37510070The benefit of using bladder sub-volume equivalent uniform dose constraints in prostate intensity-modulated radiotherapy planning
Q87671063The role of TRAIL in fatigue induced by repeated stress from radiotherapy
Q39375431Toxicity and efficacy of three dose-fractionation regimens of intensity-modulated radiation therapy for localized prostate cancer
Q55379685Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?
Q36015152Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging
Q39772182Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.
Q39736576Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
Q43271415Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer
Q36535570Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.
Q38412788What is the best way to radiate the prostate in 2016?

Search more.